Verismo Therapeutics Opens Second Site for STAR-101 Phase 1 Trial

A clinical-stage CAR-T company is currently enrolling patients to trial SynKIR™-110, an innovative treatment option for ovarian cancer, mesothelioma, and cholangiocarcinoma.

Verismo Therapeutics, which specializes in the development of the novel KIR-CAR platform technology, has launched a second clinical site at The University of Texas MD Anderson Cancer Center for its STAR-101 Phase 1 clinical trial.

STAR-101 is a multi-center clinical study aimed at assessing SynKIR™-110 in addressing ovarian cancer, malignant pleural mesothelioma, and cholangiocarcinoma cases where mesothelin is overexpressed.

Dr. Bryan Kim, Co-Founder and CEO of Verismo Therapeutics, stated, “This achievement is a significant step towards our ambition to make SynKIR™-110 available to the widest range of patients. We appreciate the collaboration with Dr. Mehmet Altan and his team at MD Anderson, which is crucial for advancing our mission.”

The FDA has approved the initiation of this clinical trial for SynKIR™-110 in multiple centers. The first site to participate was the Hospital of the University of Pennsylvania. SynKIR™-110 has also received Orphan Drug Designation and Fast Track Designation for targeting mesothelin-expressing mesotheliomas.

The KIR-CAR platform involves a dual-chain CAR T cell therapy that maintains antitumor T cell activity even in challenging tumor environments. DAP12 is used as a costimulatory molecule that enhances and sustains T cell function, chimeric receptor expression, and long-term persistence, leading to continuous regression of solid tumors in preclinical models. This platform is being combined with emerging technologies such as in vivo gene engineering, advanced cell manufacturing, and combinational therapies providing a potential next-generation immunotherapy for patients.

Verismo Therapeutics is leading the innovation in dual-chain KIR-CAR technology and is currently investigating SynKIR™-110 in human trials for advanced solid tumors. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!